Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $45.3 million.

  • Janux Therapeutics' Operating Expenses rose 2472.37% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.3 million, marking a year-over-year increase of 5582.92%. This contributed to the annual value of $109.4 million for FY2024, which is 3500.16% up from last year.
  • Per Janux Therapeutics' latest filing, its Operating Expenses stood at $45.3 million for Q3 2025, which was up 2472.37% from $45.1 million recorded in Q2 2025.
  • Janux Therapeutics' Operating Expenses' 5-year high stood at $45.3 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $21.1 million (2022), whereas its average is $22.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 86035.03% in 2021, then plummeted by 1190.37% in 2023.
  • Janux Therapeutics' Operating Expenses (Quarter) stood at $15.1 million in 2021, then surged by 39.75% to $21.1 million in 2022, then decreased by 11.9% to $18.6 million in 2023, then soared by 56.05% to $29.0 million in 2024, then soared by 55.92% to $45.3 million in 2025.
  • Its last three reported values are $45.3 million in Q3 2025, $45.1 million for Q2 2025, and $34.9 million during Q1 2025.